{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:40:45Z","timestamp":1792208445623,"version":"4.4.0"},"reference-count":59,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PCS 183410"],"award-info":[{"award-number":["PCS 183410"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["CRC\u20102023\u201000370"],"award-info":[{"award-number":["CRC\u20102023\u201000370"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We conducted a systematic review of clinical trials and cohort studies on HIV post\u2010exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Medline and Embase (July 2017\u2013June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and\/or moderate to severe adverse events. Two reviewers independently screened abstracts and publications and extracted data from eligible articles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 5226 abstracts screened, we retrieved 112 full\u2010text articles and included 22. Median study size was 160 (range\u2009=\u200952\u201326\u2009988) participants. Regimens included DTG\u2009+\u2009TDF\/XTC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094, 18%), EVG\/c\/TDF\/FTC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094, 18%), BIC\/TAF\/FTC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094, 18%), RAL\u2009+\u2009TDF\/FTC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094, 18%), EVG\/c\/TAF\/FTC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093, 14%), RPV\/TDF\/FTC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092, 9%), DOR\/TDF\/FTC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092, 9%), MVC\u2009+\u2009TDF\/FTC (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091, 5%), a wide variety of protease inhibitor\u2010based regimens (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097, 32%) and novel combinations with the injectable fusion inhibitor albuvirtide (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091, 5%); a third of studies included three or more regimens (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20098, 36%). Among studies examining PEP completion rates (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200912, 55%), cumulative completion rate was 86.6% (7779\/8983 PEP episodes) and appeared highest for RAL\u2009+\u2009TDF\/FTC, BIC\/FTC\/TAF and DOR\/TDF\/3TC at 96.4%, 96.3% and 95.0%, respectively. PEP tolerability was good, with few discontinuations due to adverse events; where data were available, this was lowest for INSTI\u2010based regimens at 0.5% (pooled across two studies) for RAL\u2009+\u2009TDF\/FTC, 1.0% (1\/99) for DTG\u2009+\u2009TDF\/XTC, 1.8% (2\/109) for BIC\/TAF\/FTC and zero with albuvirtide (0\/198). HIV seroconversions were rare (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095\/8134, 0.06%) and often related to premature PEP discontinuation or repeated exposures.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Multiple PEP regimens have been associated with high completion, good tolerability and rare seroconversion, supporting their inclusion in clinical guidelines.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70860","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:01:42Z","timestamp":1792206102000},"source":"Crossref","is-referenced-by-count":0,"title":["Systematic review of clinical trials and cohort studies evaluating HIV post\u2010exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5138-5153","authenticated-orcid":false,"given":"Stanley O.","family":"Onyegbule","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases St. Michael's Hospital  Toronto Ontario Canada"},{"name":"MAP Centre for Urban Health Solutions St Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Habib","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases St. Michael's Hospital  Toronto Ontario Canada"},{"name":"MAP Centre for Urban Health Solutions St Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rija","family":"Khalid","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases St. Michael's Hospital  Toronto Ontario Canada"},{"name":"MAP Centre for Urban Health Solutions St Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Tu","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases St. Michael's Hospital  Toronto Ontario Canada"},{"name":"MAP Centre for Urban Health Solutions St Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Yoong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy St. Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaris","family":"Swidrovich","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wale","family":"Ajiboye","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases St. Michael's Hospital  Toronto Ontario Canada"},{"name":"MAP Centre for Urban Health Solutions St Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"O'Byrne","sequence":"additional","affiliation":[{"name":"School of Nursing University of Ottawa  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameeta E.","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine University of Alberta  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Guy","family":"Baril","sequence":"additional","affiliation":[{"name":"Clinique de m\u00e9decine urbaine du Quartier latin and CHUM (Centre hospitalier de l'universit\u00e9 de Montr\u00e9al)  Montr\u00e9al Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Sotindjo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Infectious Disease, Division of Adolescent Health and Medicine University of British Columbia, Vancouver, BC Children's Hospital  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark W.","family":"Hull","sequence":"additional","affiliation":[{"name":"Department of Medicine University of British Columbia  Vancouver British Columbia Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3069-2875","authenticated-orcid":false,"given":"Darrell H. S.","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases St. Michael's Hospital  Toronto Ontario Canada"},{"name":"MAP Centre for Urban Health Solutions St Michael's Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"UNAIDS.Global AIDS report \u2013 the urgency of now: AIDS at a crossroads.2024. Accessed October 23 2024.https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2024-unaids-global-aids-update_en.pdf"},{"key":"e_1_2_11_3_1","unstructured":"Government of Canada.HIV in Canada: 2024 surveillance highlights.2024. Accessed December 5 2025.https:\/\/www.canada.ca\/en\/public\u2010health\/services\/diseases\/hiv\u2010aids\/health\u2010professionals\/surveillance\u2010highlights.html"},{"key":"e_1_2_11_4_1","unstructured":"Public Health Agency of Canada.HIV in Canada surveillance report to December 31 2022.2024. Accessed October 23 2024. Available at:http:\/\/health\/services\/publications\/diseases-conditions\/hiv-canada-surveillance-report-december-31-2022.html"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002\u20109343(97)00056\u20109"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.215"},{"key":"e_1_2_11_7_1","unstructured":"CowanE KerrCA FernandezA et al.PEP to prevent HIV infection. Baltimore (MD).2024."},{"key":"e_1_2_11_8_1","unstructured":"Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM).National guidelines for post\u2010exposure prophylaxis after non\u2010occupational and occupational exposure to HIV (second edition).2016. Accessed October 24 2024.https:\/\/ashm.org.au\/wp\u2010content\/uploads\/2022\/04\/PEP_GUIDELINES_2016.FINAL_ONLINE_VERSION\u20101.pdf"},{"key":"e_1_2_11_9_1","unstructured":"UK guideline for the use of HIV post\u2010exposure prophylaxis 2021 post consultation version 2023 amendment.2023. Accessed November 20 2024. Available at:https:\/\/www.bhiva.org\/file\/6183b6aa93a4e\/PEP-guidelines.pdf"},{"key":"e_1_2_11_10_1","volume-title":"Guidelines for HIV Post\u2010Exposure Prophylaxis","year":"2024"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.170494"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.250511"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans\u20102020\u2010054714"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.10.008"},{"key":"e_1_2_11_15_1","volume-title":"StatPearls","author":"Huynh K","year":"2025"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw365"},{"key":"e_1_2_11_17_1","unstructured":"Division of AIDS table for grading the severity of adult and pediatric adverse events version 1.0 December 2004; clarification August 2009.2009. Accessed May 5 2011.http:\/\/rsc.tech-res.com\/Document\/safetyandpharmacovigilance\/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf"},{"key":"e_1_2_11_18_1","unstructured":"Covidence systematic review software. Veritas Health Innovation. Melbourne Australia. Available atwww.covidence.org"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm\u20102022\u2010112102"},{"key":"e_1_2_11_21_1","unstructured":"HartlingL HammM MilneA et al.Validity and inter\u2010rater reliability testing of quality assessment instruments. Rockville (MD).2012."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197\u20102456(86)90046\u20102"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1214\/aoms\/1177729756"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1757177417746733"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003282"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans\u20102024\u2010056109"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky547"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010023\u201008544\u2010x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans\u20102022\u2010055622"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010024\u201009407\u20109"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz577"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12880"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx246"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12797"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad374"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002494"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002912"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001440"},{"key":"e_1_2_11_39_1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3855\/jidc.12214","article-title":"High post\u2010exposure prophylaxis uptake but low completion rates and HIV testing follow\u2010up in health workers, Harare, Zimbabwe","volume":"15","author":"Mushambi F","year":"2021","journal-title":"J Infect Dev Ctries"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.ijmr_892_23"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121\u2010021\u201000540\u20105"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12938"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_496_22"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027563"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000218543.46963.6d"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyq057"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(09)70021\u20100"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000298"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.26454"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0062"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans\u20102016\u2010052623"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834f32d8"},{"key":"e_1_2_11_53_1","unstructured":"HullM LachowskyN MooreDM et al.High incidence of subsequent HIV seroconversion amongst MSM accessing recurrent non\u2010occupational post\u2010exposure prophylaxis (NPEP) in Vancouver BC. 25th annual Canadian conference on HIV\/AIDS research abstract EPH12.2016Winnipeg Canada."},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010021\u201021485\u2010w"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1177\/2325958220939763"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13310"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461\u2010013\u20100567\u20100"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S192735"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.13.6087\u20106095.2000"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70234"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70860","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70860","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70860","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:01:52Z","timestamp":1792206112000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":59,"alternative-id":["10.1002\/bcp.70860"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70860","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"article-number":"bcp.70860"}}